Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14727MR)

This product GTTS-WQ14727MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14727MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6259MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15545MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ11945MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ2514MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ10189MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ13407MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ11258MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ5561MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW